Clinical trial · Interventional
Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Role of 18FDG PET in the Evaluation of Early Response to Maintenance Treatment With Bevacizumab or Pemetrexed in Advanced Non-small-cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non small cell lung cancer is the first cause of cancer related death in France and is becoming an increasing health problem in developing countries. Recently for patient with no progression disease after first line chemotherapy, new therapies were validated in maintenance (bevacizumab) or switch maintenance treatment (erlotinib, pemetrexed) with improved survival. Until now, determination of efficiency of treatment is only based on morphological response (RECIST) and remains inappropriate to such cytostatic drugs for which there is no anatomical lesion modification. Nuclear Medicine and especially 18-FDG Positron Emission Tomography (PET) offers a biologically relevant tool for assessment of tumour response therapies. The assumption of the study is that FDG PET would allow to earlier detect a lack of response, thereafter, to modify an ineffective treatment. Indeed, nowadays the treatment is maintained up to evidence of progression disease. However, despite the increasing use of FDG PET for predicting therapeutic response, there are no validated criteria for judging response of maintenance therapy in non-small cell lung cancer. It seems necessary to determine standardized criteria response, earlier during the course of maintenance therapy in patient with non small cell lung cancer. The final aim is to optimize survival by an adapted metabolic imaging guided therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET scan imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental
- description
- Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
- interventionNames
- Procedure: PET scan imaging
Primary outcomes (1)
- measure
- progression free survival
- timeFrame
- 16 weeks after the start of maintenance therapy
- description
- time between the start of maintenance therapy and progression
Secondary outcomes (1)
- measure
- progression free survival
- timeFrame
- on year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age superior to 18 years old * Effective contraception method or negative pregnancy test at the inclusion * OMS inferior or equal to 1 * Non-small cell lung cancer stage IIIb or IV * Non progressive disease after at lest 4 cycles of platinum-based chemotherapy * Eligible fo maintenance therapy with bevacizumab and/or pemetrexed * Inform consent signed Exclusion Criteria: * Evolution of a second cancer in the 3 years before inclusion * Pregnancy or breast-feeding * poorly controlled diabetes * curatorship or guardianship * contraindication to iodinated contrast agents * participation to another clinical research with an experimental drug * impossible decubitus * not possibility to follow-up the procedures of the study due to geographic, social or psychic reasons
References
Publications (0)
Data not yet available